The approach lets researchers monitor protein complexes in vivo and could aid investigations into how different drugs and diseases modify these structures.
The firm posted revenues of $530.5 million, with organic growth at 4 percent and acquisitions and currency effects adding 4 percent and 5 percent, respectively.
Revenue increases for the firm's for high-throughput genomics and mass cytometry products were offset by declines in single-cell genomics product sales.
DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.
The approach, called RaPID, could enable more-efficient and less-biased in vivo measurements of RNA-protein interactions.
Researchers also used citrus genomes to untangle their relationships and suggest new taxonomic classifications.
SUNY researchers used a large-scale proteome study to determine that treatment with birinapant and paclitaxel suppresses the Warburg effect in pancreatic cancer.
The PCR-based methylation assay is intended to help predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy.
Based on technology developed at Mass General, the platform will allow the company and its customers to add protein detection to nucleic acid analysis.
The parties will use Somalogic's SomaScan platform to investigate the ability of protein measurements to affect patient care in a variety of clinical areas.
A genome-wide association study of nearly 60 quantitative traits highlighted the links between genes, clinical measurements, and disease.
The companies will offer a system for the identification and quantitation of metabolites in biological samples.
Working with Case Western Reserve University, the firm will sequence fecal samples from individuals diagnosed with autism and provide results for free to the research community.
The Boston-based startup wants to help individuals interpret their HLA data for ancestry and health, and participate in research studies.
Genome Canada and its partners recently funded two new initiatives with C$255 that will back precision medicine, genomics, and technology development.
Researchers found methylation mediators of obesity and other metabolic features by profiling individuals born after a famine called the Dutch Hunger Winter.
A study published in Nature this week is the latest to suggest that blood-based protein markers could be indicative of amyloid deposit levels in the brain.
The firm said its columns, which use patterned silicon wafers, improve on existing LC systems in terms of robustness, reproducibility, and depth of separation.
As organisms age, their transcriptomic signatures shift from looking more like those observed in cancer to those seen in degenerative chronic diseases.
The partners are working together to build a registry of genetic and other data for a study of sleep in more than 30,000 individuals.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.